In Part 2 of our conversation with Charles Miller from Scenic City Neurotherapy, we get into the practical side of his controversial "collective lie" thesis from Part 1.
Charles walks through his MSKIT (Minimally Stimulated Ketamine Infusion Therapy) approach, explaining when he believes therapeutic integration should actually happen: weeks after treatment during the neuroplasticity window, not during altered states. He addresses how he manages patient expectations around epiphanies and insights, arguing these are retrospective brain noise rather than therapeutic mechanisms.
You'll hear Charles use memorable analogies—from cheese obsessions to rollercoaster highs—to explain why he believes the psychedelic experience itself isn't doing the heavy lifting. He makes the case that ketamine is upgrading synaptic function, not providing mystical cures, and that the real work happens when patients are sober and doing therapy afterward.
Through detailed audio sidebars, we explore the crucial relationship between BDNF and sleep (and why post-treatment rest matters more than most clinics acknowledge), and examine the metabolite pathway that creates ketamine's addiction potential.
Charles also shares his vision for the future of ketamine therapy, advocating for greater scientific rigor and proper medical oversight while critiquing the growing trend of unqualified providers administering ketamine.
If you're questioning whether the approaches many of us have been using actually serve our patients best, this conversation will give you a lot to think about.
What You'll Learn in This Episode
· Patient education strategies - How to remove performance pressure by explaining "you can't make this work better or worse" and framing treatment as physiology, not psychology
· Managing epiphanies and insights - Charles's perspective on why experiences are retrospective brain noise rather than therapeutic mechanisms, and how to validate without overemphasizing
· BDNF and sleep optimization - The critical relationship between post-treatment sleep quality and neuroplasticity consolidation that many clinics overlook
· Ketamine's addiction pathway - Understanding the hydroxynorketamine metabolite mechanism and why "more is not better" with dosing protocols
· Pain protocol applications - How he incorporates NAD, lidocaine, magnesium, and anti-inflammatories for comprehensive chronic pain treatment
· Future field vision - Charles's call for greater scientific rigor, proper medical oversight, and evidence-based protocols over speculative experiential approaches
Key Takeaways
· Therapeutic integration may be more effective up to weeks after ketamine treatment when the neuroplasticity window is active, rather than during altered states when processing capacity is diminished
· Patient education could focus on removing performance pressure by explaining ketamine as physiological process rather than psychological work, helping patients understand "you can't mess this up"
· Ketamine experiences might be retrospective rather than revelatory, reflecting existing knowledge without noise rather than generating new insights, which suggests focusing on post-treatment integration work
· Sleep quality in days following ketamine treatment could significantly impact neuroplasticity consolidation, as BDNF release during rest helps lock in synaptic changes initiated by treatment
· Ketamine's addiction potential may stem from the hydroxynorketamine metabolite binding to opioid receptors at high doses, supporting protocols that emphasize "more is not better" dosing approaches
· Mental health symptoms might represent accurate emotional responses to synaptic dysfunction rather than diseases themselves, with ketamine enhancing processing speed and accuracy rather than changing brain content
· Providers could benefit from understanding ketamine's "dirty drug" pharmacology, including sodium channel blocking effects that contribute to dissociation and can be addressed with targeted adjuncts like lidocaine
Episode 53 show notes:
00:00:00 - Teaser: This Is Not Magic, This Is Science
00:00:17 - Introduction and Part 2 Setup
00:01:54 - When Therapy Should Actually Happen: Physical Therapy Doesn't Occur During Surgery
00:02:48 - Optimal Timing for Therapeutic Integration: The Weeks That Follow Treatment
00:05:31 - The Science Behind Post-Treatment Rest: BDNF Release and Sleep
00:07:25 - Audio Sidebar: BDNF and Sleep Connection
00:09:29 - Managing Patient Epiphanies: The Cheese Story and Brain Noise
00:13:30 - Mental Health as Synaptic Processing Speed
00:16:45 - Why Experience-Driven Treatment Would Require Daily Ketamine
00:18:04 - MSKIT Protocol: Minimally Stimulated Ketamine Infusion Therapy
00:22:12 - Minimally Stimulating Environment: Binaural Beats and Brain Noise
00:25:30 - Pain Protocols and the "Dirty Drug" Concept
00:26:57 - Audio Sidebar: Ketamine's Metabolite Addiction Pathway
00:30:31 - Future Vision: Greater Rigor and Medical Oversight
00:34:56 - Rapid Fire Personal Questions
00:42:55 - Final Thoughts and Episode Wrap-up
Thanks for listening
📋 Professional Education Disclaimer: Content for licensed healthcare providers for educational purposes only. Does not constitute medical, legal, or business advice. Always consult qualified professionals for specific clinical and practice decisions.
Connect with Charles Miller & Scenic City Neurotherapy:
Website
Instagram
LinkedIn
📝 Complete show notes with resources and links, please visit www.ketaminestartup.com/podcast/episode-053
Follow us on
LinkedIn
Ketamine StartUp Website
YouTube
🚀Want to fast track launching your ketamine clinic? If so, download our free checklist.
